Handelsbanken Fonder AB Sells 30,000 Shares of Immunome, Inc. (NASDAQ:IMNM)

Handelsbanken Fonder AB cut its holdings in shares of Immunome, Inc. (NASDAQ:IMNM) by 13.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 200,000 shares of the company’s stock after selling 30,000 shares during the period. Handelsbanken Fonder AB owned 0.32% of Immunome worth $2,124,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Stoneridge Investment Partners LLC bought a new position in Immunome in the fourth quarter worth about $123,000. Intech Investment Management LLC purchased a new position in shares of Immunome in the 3rd quarter worth approximately $219,000. Three Bridge Wealth Advisors LLC bought a new position in shares of Immunome during the 4th quarter worth approximately $293,000. JPMorgan Chase & Co. lifted its position in Immunome by 6.6% during the third quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company’s stock valued at $359,000 after acquiring an additional 1,520 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in Immunome in the third quarter valued at approximately $363,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on IMNM shares. Piper Sandler decreased their price objective on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Stephens began coverage on Immunome in a research note on Friday, November 8th. They issued an “overweight” rating and a $30.00 price target for the company. Finally, Wedbush restated an “outperform” rating and set a $33.00 price target on shares of Immunome in a research note on Monday, January 13th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Immunome has an average rating of “Buy” and an average price target of $28.60.

Immunome Stock Up 3.4 %

Immunome stock opened at $9.67 on Wednesday. The stock has a 50-day moving average price of $10.44 and a 200 day moving average price of $12.25. The company has a market capitalization of $771.44 million, a price-to-earnings ratio of -1.19 and a beta of 1.90. Immunome, Inc. has a 52 week low of $8.93 and a 52 week high of $30.96.

Insider Buying and Selling

In related news, CEO Clay B. Siegall purchased 150,000 shares of the business’s stock in a transaction on Friday, January 31st. The shares were bought at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the transaction, the chief executive officer now owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. This trade represents a 28.87 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.60% of the stock is currently owned by corporate insiders.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.